Nausheen Ahmed, MD, on the Impact of Prior Treatments on the Safety of Brexu-cel

Video

The assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed real-world safety outcomes for brexu-cel in patients with r/r MCL.

“...This is the largest analysis to date looking at the effectiveness and the safety data for brexu-cel in the real-world population. We see that the outcomes were fairly similar to the ZUMA-2 outcomes...”

Kite Pharma’s brexucabtagene autoleucel (brexu-cel, Tecartus) was approved by the FDA as a second-line treatment for adult patients with relapsed/refractory (r/r) mantle cell lymphoma (MCL) in 2020 based on results from the phase 2 ZUMA-2 clinical trial (NCT02601313).1 The FDA indication does not require a specific first-line therapy to have been used; as such, patients in real-world settings have varied treatment histories when receiving brexu-cel for r/r MCL.

Nausheen Ahmed, MD, an assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center, presented a study entitled “Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory mantle cell lymphoma: a CIBMTR subgroup analysis by prior treatment” at the European Hematology Association (EHA) 2023 Congress, held June 8-11, both virtually and in Frankfurt, Germany.2 The study consisted of an analysis of efficacy and safety outcomes from a subgroup of 380 patients treated with brexu-cel who were registered in the Center for International Blood and Marrow Transplant Research (CIBMTR) observational database, with a focus on examining how prior treatment impacted these outcomes.

In an interview with CGTLive™’s sister publication OncLive™, Ahmed discussed the safety findings from the study. She emphasized that the safety outcomes in the real-world data were largely consistent with the safety outcomes in ZUMA-2, noting that 88% of patients experienced cases of cytokine release syndrome (CRS), 10% of patients experienced grade 3 or higher CRS cases, 60% of patients experienced cases of immune effector cell-associated neurotoxicity syndrome (ICANS), and 28% of patients experienced cases of grade 3 or higher ICANS. She also discussed findings from the multivariate regression analysis used to examine the impact of prior treatment history in the real-world data. Ahmed noted that patients who had been previously treated with bendamustine tended to have less high-grade ICANS but a greater risk of prolonged cytopenias. She also pointed out that patients who had received 1 to 2 prior lines of therapy tended to have higher grade CRS compared to patients who had received 3 or more prior lines of therapy. Ahmed additionally gave a summary of the main efficacy findings she presented and emphasized the importance of keeping in mind the short follow-up time for the data presented.

Click here for more coverage of EHA 2023.

REFERENCE
1. U.S. FDA Approves Kite’s Tecartus™, the first and only CAR T treatment for relapsed or refractory mantle cell lymphoma. News release. Kite, a Gilead Company. July 24, 2020. Accessed June 8, 2023. https://www.businesswire.com/news/home/20200724005428/en/
2. Ahmed N, Kambhampati S, Hamadani M, et al. Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory mantle cell lymphoma: a CIBMTR subgroup analysis by prior treatment. Presented at: the European Hematology Association (EHA) 2023 Congress, June 8-11, held both virtually and in Frankfurt, Germany. Abstract #S220
Related Videos
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
© 2024 MJH Life Sciences

All rights reserved.